Drug-induced Valvulopathy: An Update
暂无分享,去创建一个
[1] B. Carabello,et al. Valvular heart disease. , 1997, The New England journal of medicine.
[2] A. Desmoulière,et al. The Myofibroblast: one function, multiple origins , 2010 .
[3] M. Yacoub,et al. Molecular characterization of interstitial cells isolated from human heart valves. , 2000, The Journal of heart valve disease.
[4] V. Ferrans,et al. 35 – Cardiovascular and Skeletal Muscle Systems , 2002 .
[5] W. Edwards,et al. Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.
[6] R. Levy,et al. Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. , 2009, The American journal of pathology.
[7] A. Gotlieb,et al. Cell biology of valvular interstitial cells. , 1996, The Canadian journal of cardiology.
[8] R. Sorelle. Diet drug maker agrees to $3.75 billion settlement. , 1999, Circulation.
[9] Frederick J Schoen,et al. New frontiers in the pathology and therapy of heart valve disease: 2006 Society for Cardiovascular Pathology, Distinguished Achievement Award Lecture, United States-Canadian Academy of Pathology, Atlanta, GA, February 12, 2006. , 2006, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[10] C. Yeh,et al. Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. , 2009, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[11] I. Gessner,et al. Effects of prenatal co-administration of phentermine and dexfenfluramine in rats. , 1999, European journal of pharmacology.
[12] K. Miyazono,et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. , 1993, The American journal of pathology.
[13] Bryan L. Roth,et al. Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment , 2009, Molecular Pharmacology.
[14] P. A. Wallenborn,et al. Agammaglobulinemia , 1960 .
[15] E. Hay,et al. Cell Biology of Extracellular Matrix , 1988, Springer US.
[16] G. Mazzotti,et al. Trends in ecstasy use in the United States from 1995 to 2001: comparison with marijuana users and association with other drug use. , 2005, Experimental and clinical psychopharmacology.
[17] F. Barry. Proteoglycans: structure and function. , 1990, Biochemical Society transactions.
[18] P. Franken,et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. , 2007, The American journal of cardiology.
[19] A. Bossuyt,et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. , 2007, European heart journal.
[20] J. Van Dorpe,et al. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. , 1996, The Journal of heart valve disease.
[21] V. Setola,et al. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen–phen’ , 2005, Expert opinion on drug metabolism & toxicology.
[22] Elaine L. Lee,et al. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. , 2009, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[23] R. Markwald,et al. An In Vivo Analysis of Hematopoietic Stem Cell Potential: Hematopoietic Origin of Cardiac Valve Interstitial Cells , 2006, Circulation research.
[24] B. Roth,et al. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.
[25] Ut Southwestern. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation , 2005 .
[26] Kristi S Anseth,et al. Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 interactions with matrix molecules. , 2005, Matrix biology : journal of the International Society for Matrix Biology.
[27] M. Yacoub,et al. Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. , 2000, The Journal of heart valve disease.
[28] A. Verma. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease , 2008 .
[29] Nicola Fox,et al. Cardiovascular system. , 2007, Nursing Standard.
[30] F. Schoen,et al. Human Semilunar Cardiac Valve Remodeling by Activated Cells From Fetus to Adult: Implications for Postnatal Adaptation, Pathology, and Tissue Engineering , 2006, Circulation.
[31] Frederick J Schoen,et al. Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. , 2005, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[32] P. Lantelme,et al. Valvular heart disease associated with fenfluramine detected 7 years after discontinuation of treatment. , 2007, The Annals of thoracic surgery.
[33] K. J. Grande-Allen,et al. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading. , 2004, Glycobiology.
[34] D. Mulholland,et al. Cardiac valve interstitial cells: regulator of valve structure and function. , 1997 .
[35] R. Lipton,et al. Age-dependent prevalence and clinical features of migraine , 2006, Neurology.
[36] R. Visse,et al. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases : Structure , 2003 .
[37] P. Libby,et al. Activated Interstitial Myofibroblasts Express Catabolic Enzymes and Mediate Matrix Remodeling in Myxomatous Heart Valves , 2001, Circulation.
[38] B. Largent,et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.
[39] F. Viallet,et al. Fibrotic valvular heart disease subsequent to bromocriptine treatment. , 2002, Cardiology in review.
[40] K. A. Misch. Development of heart valve lesions during methysergide therapy. , 1974, British medical journal.
[41] M. Millan,et al. Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes , 2002, Journal of Pharmacology and Experimental Therapeutics.
[42] R. Horowski,et al. Agonism at 5-HT2B receptors is not a class effect of the ergolines. , 2005, European journal of pharmacology.
[43] Frederick J. SchoenT. Review Article Cardiac valves and valvular pathology B Update on function, disease, repair, and replacement , 2005 .
[44] P. Franken,et al. Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. , 2009, American journal of physiology. Heart and circulatory physiology.
[45] A. Gotlieb,et al. Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells. , 2008, The American journal of pathology.
[46] M. Hamon,et al. Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice , 2005, Circulation.
[47] A. Verma,et al. Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation , 2008 .
[48] V. Joag,et al. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. , 2007, The American journal of pathology.
[49] Hans Kresse,et al. Proteoglycans of the extracellular matrix and growth control , 2001, Journal of cellular physiology.
[50] H. Schoon,et al. Distribution of extracellular matrix components in normal and degenerated canine tricuspid valve leaflets. , 2009, Journal of comparative pathology.
[51] W. Edwards,et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. , 2001, The Journal of heart valve disease.
[52] W. Edwards,et al. Valvular heart disease in patients taking pergolide. , 2002, Mayo Clinic proceedings.
[53] L. Weinrauch,et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.
[54] H. Jick. Heart valve disorders and appetite-suppressant drugs. , 2000, JAMA.
[55] A. Tajik,et al. Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations , 1992, Annals of Internal Medicine.
[56] P. Wolf,et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.
[57] Craig A Simmons,et al. Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. , 2009, The American journal of pathology.
[58] C. Elangbam,et al. 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[59] R. Levy,et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. , 2002, The American journal of pathology.
[60] A. Fishman. Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.
[61] P. Greaves. Comprar Histopathology of Preclinical Toxicity Studies, 3rd Edition. Interpretation and Relevance in Drug Safety Evaluation | Peter Greaves | 9780444527714 | Elsevier Science , 2007 .
[62] G. Kissling,et al. Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy--a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[63] Craig A. Simmons,et al. Spatial Heterogeneity of Endothelial Phenotypes Correlates With Side-Specific Vulnerability to Calcification in Normal Porcine Aortic Valves , 2005, Circulation research.
[64] Gerard C Blobe,et al. Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.
[65] B L Bass,et al. Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. , 1994, The Journal of surgical research.
[66] R. M. Lightfoot,et al. 5-Hydroxytryptamine (5HT) Receptors in the Heart Valves of Cynomolgus Monkeys and Sprague-Dawley Rats , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[67] J. Massagué,et al. Smad transcription factors. , 2005, Genes & development.
[68] M. Lopez-Ilasaca. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. , 1998, Biochemical pharmacology.
[69] T. Ryan,et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. , 2000, Circulation.
[70] L. Leinwand,et al. Valvular Myofibroblast Activation by Transforming Growth Factor-&bgr;: Implications for Pathological Extracellular Matrix Remodeling in Heart Valve Disease , 2004, Circulation research.
[71] C. Pollick. Aminorex to Fen/Phen: an epidemic foretold. , 1999, Circulation.
[72] J. Massagué,et al. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.
[73] Robert M. Nerem,et al. Transcriptional Profiles of Valvular and Vascular Endothelial Cells Reveal Phenotypic Differences: Influence of Shear Stress , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[74] R. Khokha,et al. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors , 2005, Thrombosis and Haemostasis.
[75] R. Fossmark,et al. Long-Term Serotonin Administration Induces Heart Valve Disease in Rats , 2005, Circulation.
[76] W. Weidman. Second natural history study of congenital heart defects. , 1993, Circulation.
[77] Karen Birmingham,et al. the heart , 2002, Nature.
[78] M R de Leval,et al. Innervation of human atrioventricular and arterial valves. , 1996, Circulation.
[79] R. Visse,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .
[80] Giulio Gabbiani,et al. Perspective Article: Tissue repair, contraction, and the myofibroblast , 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[81] P. Hopkins,et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals , 2008, BMC medicine.
[82] K. Miyazono,et al. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. , 1997, Nature.
[83] R. Rothman,et al. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. , 2009, American journal of therapeutics.
[84] M. Worsham,et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. , 1997, MMWR. Morbidity and mortality weekly report.
[85] F. Grandas,et al. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review , 2009, Journal of Neural Transmission.
[86] K. Donnelly. Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases , 2008, Toxicologic pathology.
[87] W. Poewe,et al. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.
[88] J. F. Keane,et al. Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. , 1993, Circulation.
[89] J. Graham. Cardiac and pulmonary fibrosis during methysergide therapy for headache. , 1967, Transactions of the American Clinical and Climatological Association.
[90] H. Schoon,et al. Histomorphological findings and expression of matrix metalloproteinases and their tissue specific inhibitors (TIMPs) in normal tricuspid valves and in chronic tricuspid valvular disease in dogs. , 2010, Veterinary journal.
[91] R. Markwald,et al. Periostin regulates atrioventricular valve maturation. , 2008, Developmental biology.
[92] A. J. Hauck,et al. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. , 1990, Archives of pathology & laboratory medicine.
[93] T. Ryan,et al. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. , 2002, American heart journal.
[94] P. Greaves. 7 – Cardiovascular System , 2007 .
[95] D. Heistad,et al. Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. , 2009, American journal of physiology. Heart and circulatory physiology.
[96] H. Schoon,et al. An immunohistochemical study of the role of matrix metalloproteinases and their tissue inhibitors in chronic mitral valvular disease (valvular endocardiosis) in dogs. , 2009, Veterinary journal.
[97] B. McManus,et al. Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? , 2002, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[98] A. Gotlieb,et al. Cardiac valve interstitial cells secrete fibronectin and form fibrillar adhesions in response to injury. , 2007, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[99] D. E. Nichols,et al. Serotonin receptors. , 2008, Chemical reviews.
[100] V. Setola,et al. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. , 2003, Molecular pharmacology.
[101] B. Fanburg,et al. A new role for an old molecule: serotonin as a mitogen. , 1997, The American journal of physiology.
[102] A. Feldman,et al. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. , 2000, Cardiovascular research.
[103] S. Bressler,et al. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. , 2004, Critical reviews in eukaryotic gene expression.
[104] Patrick Santens,et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease , 2004, The Lancet.
[105] R. Iozzo,et al. The role of decorin in collagen fibrillogenesis and skin homeostasis , 2002, Glycoconjugate Journal.
[106] T. Wight,et al. Versican: a versatile extracellular matrix proteoglycan in cell biology. , 2002, Current opinion in cell biology.
[107] Keith E. Volmar,et al. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. , 2001, Archives of pathology & laboratory medicine.
[108] B. Roth. Drugs and valvular heart disease. , 2007, The New England journal of medicine.
[109] G. Bray,et al. Obesity , 2008, Annals of Internal Medicine.
[110] W. Chitwood,et al. Histologic changes in three explanted native cardiac valves following use of fenfluramines. , 1999, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[111] P. Lecompte,et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. , 1974, American heart journal.